Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-L Vaccine with Montanide and Poly-ICLC in Ovarian Cancer
NCT02452775Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous oxidized tumor cell lysate vaccine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Abramson Cancer Center. Primary endpoint: Numbers of Adverse Events at 3.5 years. Started May 2015; status: terminated.
02
Drugs
autologous oxidized tumor cell lysate vaccine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02452775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452775.